Advances in molecular classification and precision oncology in hepatocellular carcinoma

HepatitisHepatology

Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study

J Hepatol.

Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, Cavalletto L, Gambato M, Russo FP, Burra P, Vincenzi V, Scotton PG, Panese S, Tempesta D, Bertin T, Carrara M, Carlotto A, Capra F, Carolo G, Scroccaro G, Alberti A

doi: 10.1016/j.jhep.2018.03.009.

Gastrointestinal Cancer

Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma

J Hepatol.

Ricke J, Klumpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni E, Gasbarrini A, Pech M, Peck-Radosavljevic M, Popovič P, Rosmorduc O, Schott E, Seidensticker M, Verslype C, Sangro B, Malfertheiner P

doi: 10.1016/j.jhep.2019.08.006.

Hepatology

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Lancet Gastroenterol Hepatol

Qin S, Li Q, Gu S, Chen X, Lin L, Wang Z, Xu A, Chen X, Zhou C, Ren Z, Yang L, Xu L, Bai Y, Chen L, Li J, Pan H, Cao B, Fang W, Wu W, Wang G, Cheng Y, Yu Z, Zhu X, Jiang D, Lu Y, Wang H, Xu J, Bai L, Liu Y, Lin H, Wu C, Zhang Y, Yan P, Jin C, Zou J

doi: 10.1016/S2468-1253(21)00109-6

Gallbladder and Biliary Diseases

Liquid biopsy in the clinical management of hepatocellular carcinoma

Gut

von Felden J, Garcia-Lezana T, Schulze K, Losic B, Villanueva A

doi: 10.1136/gutjnl-2019-320282

Gastrointestinal Cancer

Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial)

Eur J Cancer

Pereira H, Bouattour M, Dioguardi Burgio M, Assenat E, Grégory J, Bronowicki JP, Chatellier G, Vilgrain V, SARAH Trial Group.

doi: 10.1016/j.ejca.2021.05.032

Further Publications

CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis

J Hepatol

Kudo M, Matilla A, Santoro A, Melero I, Gracián AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, Tschaika M, Wisniewski T, Sangro B

doi: 10.1016/j.jhep.2021.04.047

Gastrointestinal CancerHepatology

Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection

J Hepatol.

Marasco G, Colecchia A, Colli A, Ravaioli F, Casazza G, Reggiani MLB, Cucchetti A, Cescon M, Festi D

doi: 10.1016/j.jhep.2018.10.022.

Further Publications

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Lancet Gastroenterol Hepatol

Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, López C, Sung M, Mody K, Ohtsuka T, Tamai T, Bennett L, Meier G, Breder V

doi: 10.1016/S2468-1253(21)00110-2

Hepatology

Prognostic significance of the controlling nutritional status (CONUT) score in patients undergoing hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis

BMC Gastroenterol.

Takagi K, Domagala P, Polak WG, Buettner S, Ijzermans JNM

doi: 10.1186/s12876-019-1126-6.

Related content

Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study

Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Liquid biopsy in the clinical management of hepatocellular carcinoma

Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial)

CheckMate 040 Cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis

Role of liver and spleen stiffness in predicting the recurrence of hepatocellular carcinoma after resection

Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial

Prognostic significance of the controlling nutritional status (CONUT) score in patients undergoing hepatectomy for hepatocellular carcinoma: a systematic review and meta-analysis